Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyclopropane SCHEMBL28025983 | 1.00 | ALDH1A1 (0.35) | ALDH1A1TSHRKMT2AGAASMN1; SMN2 | |
| SCHEMBL10629680 | 1.00 | ALDH1A1 (0.35) | ALDH1A1TSHRKMT2AGAASMN1; SMN2 | |
| Cyclohexane SCHEMBL11220300 | 1.00 | ALDH1A1 (0.35) | ALDH1A1TSHRKMT2AGAASMN1; SMN2 | |
| SCHEMBL22105 | 0.89 | — | — | |
| SCHEMBL27922143 | 0.89 | TSHR (0.38) | ALDH1A1TSHRKMT2ASMN1; SMN2MAPT | |
| Methane SCHEMBL23927285 | 0.85 | — | — | |
| Hydrochloric Acid SCHEMBL220991 | 0.85 | — | — | |
| SCHEMBL9402771 | 0.85 | TSHR (0.36) | ALDH1A1TSHRKMT2ASMN1; SMN2MAPT | |
| SCHEMBL3312437 | 0.85 | — | — | |
| Water SCHEMBL1155773 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100266526-A1 | Combination therapy for treating hypercholesterolemia | GENZYME CORPORATION (US) | 2010-10-21 | — | — | US | disclosed |
| US-7638524-B2 | For reducing serum cholesterol in a mammal | GENZYME CORPORATION (US) | 2009-12-29 | — | — | US | disclosed |
| EP-1028717-B1 | UNSUBSTITUTED POLYDIALLYLAMINE FOR TREATING HYPERCHOLESTEROLEMIA | GELTEX PHARMA INC (US) | 2003-03-26 | — | — | EP | disclosed |
| US-20020155091-A1 | Combination therapy for treating hypercholesterolemia | GELTEX PHARMACEUTICALS, INC. | 2002-10-24 | — | — | US | disclosed |
| US-6365186-B1 | ADMINISTERING TO PATIENT UNSUBSTITUTED POLYDIALLYLAMINE POLYMER AND CHOLESTEROL-LOWERING AGENT IN THERAPEUTICALLY EFFECTIVE AMOUNT | GELTEX PHARMACEUTICALS, INC. | 2002-04-02 | — | — | US | disclosed |
| US-6264938-B1 | ADMINISTERING POLYDIALLYLAMINE AND HYDROXY-3-METHYLGLUTARYL/3-/, COENZYME A REDUCTASE | GELTEX PHARMACEUTICALS, INC. | 2001-07-24 | — | — | US | disclosed |
| US-6248318-B1 | ADMINISTERING DOSAGE INTO GASTROINTESTINAL TRACT | GELTEX PHARMACEUTICALS, INC. | 2001-06-19 | — | — | US | disclosed |
| WO-2000069446-A1 | COMBINATION THERAPY FOR TREATING HYPERCHOLESTEROLEMIA | GELTEX PHARMACEUTICALS, INC. (US) | 2000-11-23 | — | — | WO | disclosed |
| WO-2000069445-A1 | COMBINATION THERAPY FOR TREATING HYPERCHOLESTEROLEMIA | GELTEX PHARMACEUTICALS, INC. (US) | 2000-11-23 | — | — | WO | disclosed |
| EP-1028717-A2 | UNSUBSTITUTED POLYDIALLYLAMINE FOR TREATING HYPERCHOLESTEROLEMIA | GELTEX PHARMACEUTICALS, INC. (US) | 2000-08-23 | — | — | EP | disclosed |
| US-6083497-A | REMOVING BILE SALTS FROM A PATIENT BY ADMINISTERING A THERAPEUTICALLY EFFECTIVE AMOUNT OF A NON-ABSORBABLE POLYDIALLYLAMINE POLYMER | GELTEX PHARMACEUTICALS, INC. (US) | 2000-07-04 | — | — | US | disclosed |
| WO-1999022721-A2 | UNSUBSTITUTED POLYDIALLYLAMINE FOR TREATING HYPERCHOLESTEROLEMIA | GELTEX PHARMACEUTICALS, INC. (US) | 1999-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020155091-A1 | Combination therapy for treating hypercholesterolemia | PCSK9, SLC10A1, NR1H4 | ALDH1A1 2748/4885TSHR 4561/4885KMT2A 1418/4885 |
| US-20100266526-A1 | Combination therapy for treating hypercholesterolemia | PCSK9, SLC10A1, NR1H4 | ALDH1A1 2748/4885TSHR 4561/4885KMT2A 1418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.